Since accurately picking ***** to fight patients’ unique tumor mutations remains in large part a guessing game, researchers have been working on finding better approaches. An international team of investigators has developed a way of growing living Orga**ids from patients’ own tumor cells for use as a testing platform to discover which ***** work before trying them directly on the patients.
Orga**ids resemble the original Tumors much better than cell lines, having a 3D structure, a variety of cells, and similar growth characteristics. In the study published in journal Cell, the researchers grew Orga**ids from colorectal Cancer biopsies taken from 20 patients. They sequenced the DNA of the Orga**ids as well, as well as the original tumors, comparing how the pairs change over time. They discovered that similar mutations occur in the cancers and their corresponding orga**ids, pointing to the use of Orga**ids as an*accurate platform for Drug selection.
In Rspondin-based 3D cultures, Lgr5 stem cells from*multiple organs form ever-expanding epithelial Orga**ids that retain their tissue identity. We report the establishment of tumor orga**id cultures from 20 consecutive colorectal carci**ma (CRC) patients. For most, Orga**ids were also generated from adjacent **rmal tissue. Orga**ids closely recapitulate several properties of the original tumor. The spectrum of genetic changes within the “living biobank” agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor Orga**ids are amenable to high-throughput Drug screens allowing detection of gene-drug associations. As an example, a single orga**id culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than inAPC. Orga**id tech**logy may fill the gap between Cancer genetics and Patient trials, complement cell-line- and xe**graft-based Drug studies, and allow personalized therapy design.